Therapy News and Research

RSS

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Sangamo BioSciences, Inc. announced today that data from clinical, preclinical and research-stage programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in twenty presentations given by Sangamo scientists and collaborators at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.

23 May 2011

Cognitive-behavioral therapy helps treat hypochondriasis

In a study published in the current issue of Psychotherapy and Psychosomatics the mechanisms underlying improvement in hypochondriasis are examined.

23 May 2011

Cognitive behavioral group therapy may help prevent new episodes of bipolar disorder

In the current issue of Psychotherapy and Psychosomatics a randomized controlled trial indicates that group therapy may affect the course of bipolar disorder. This study evaluated the effectiveness of adjunctive cognitive behavioral group therapy to prevent recurrence of episodes in 50 euthymic patients with bipolar disorder types I and II followed up for at least 12 months in an outpatient service and whose disease was in remission.

23 May 2011

Stanford University develops stress-shielding device to reduce surgical scarring

Researchers at Stanford University have developed a special wound dressing that they report was able to significantly reduce scar tissue caused by incisions.

23 May 2011

New data from ProSavin Phase I/II trial in Parkinson's presented at ASGCT annual meeting

Oxford BioMedica, a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin for the treatment of Parkinson's disease were presented at the American Society of Gene & Cell Therapy 14th Annual Meeting held in Seattle, USA by Professor Stephane Palfi, Principal Investigator at the Henri Mondor Hospital in Paris, on Saturday 21 May 2011.

23 May 2011

Researchers discover new genes that influence severity of cystic fibrosis

Johns Hopkins Institute for Genetic Medicine researchers working as part of the North American Cystic Fibrosis Consortium have discovered two regions of the genome that affect the severity of cystic fibrosis, a genetic condition that causes scarring throughout the body, affecting most notably the pancreas and lungs.

23 May 2011

Patients with chronic heart failure can benefit from telemonitoring

Two trials presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology, will help to define the precise populations of patients with chronic heart failure in whom telemedical management delivers benefits.

23 May 2011

Patients with mild heart failure more likely to benefit from cardiac resynchronization therapy with defibrillation

Patients with dyssynchronous yet viable ventricles are most likely to benefit from cardiac resynchronization therapy combined with defibrillation, concludes the latest analysis of the MADIT CRT trial.

23 May 2011

Eplerenone reduces new onset atrial fibrillation and flutter in patients with class 2 heart failure

The aldosterone antagonist eplerenone significantly reduced the development of new onset atrial fibrillation and flutter in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial, presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology.

23 May 2011

Researchers identify new drug resistant protein in breast cancer

Researchers have identified a new protein involved in the development of drug resistance in breast cancer which could be a target for new treatments, they report today in the journal Nature Medicine.

23 May 2011

Australians discover treatment for very common female infection

Starpharma Holdings Limited has announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel® for the treatment of bacterial vaginosis (BV).

22 May 2011

Salk researchers successfully edit diseased gene in patient-specific induced pluripotent stem cells

In principle, genetic engineering is simple, but in practice, replacing a faulty gene with a healthy copy is anything but. Using mutated versions of the lamin A gene as an example to demonstrate the versatility of their virus-based approach, researchers at the Salk Institute for Biological Studies successfully edited a diseased gene in patient-specific induced pluripotent stem cells as well as adult stem cells.

21 May 2011

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Eli Lilly and Company announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma.

21 May 2011

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

Although chemotherapy is used to kill cancer cells, it can also have a strong toxic effect on normal cells such as bone marrow and blood cells, often limiting the ability to use and manage the chemotherapy treatment.

21 May 2011

Stimulating electrode array assists paralyzed man to regain voluntary movements of limbs

A team of researchers from the University of California, Los Angeles (UCLA), the California Institute of Technology (Caltech), and the University of Louisville have used a stimulating electrode array to assist a paralyzed man to stand, step on a treadmill with assistance, and, over time, to regain voluntary movements of his limbs.

21 May 2011

FDA approves SUTENT for treatment of pancreatic NET

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.

21 May 2011

Roundup: Kan. exchange blueprint coming soon; 'Most favored nation' ban passes in Conn.; Anti-fraud repeal in Calif.

In a few months, the Kansas Insurance Department is expected to release a blueprint for how a health insurance exchange might work. "We still have a lot of work to do but, so far, the process has been going really, really well," said Linda Sheppard, head of the insurance department's accident and health accident and health division.

21 May 2011

DFG to fund 60 million euros for 18 new Research Training Groups

With the aim of further strengthening early-career research in Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 18 new Research Training Groups.

21 May 2011

Medicine, osteopathy, physical therapy and chiropractic colleges collaborate to study safety in spinal manipulation

A recent team grant by the Canadian Institute for Health Research is providing an innovative approach to researching patient safety for those who provide and receive spinal-manipulative therapy. The $2-million grant over five years brings together health researchers from across Canada and will involve input from four regulatory colleges in Alberta.

21 May 2011

Therapy News and Research

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Cognitive-behavioral therapy helps treat hypochondriasis

Cognitive behavioral group therapy may help prevent new episodes of bipolar disorder

Stanford University develops stress-shielding device to reduce surgical scarring

New data from ProSavin Phase I/II trial in Parkinson's presented at ASGCT annual meeting

Researchers discover new genes that influence severity of cystic fibrosis

Patients with chronic heart failure can benefit from telemonitoring

Patients with mild heart failure more likely to benefit from cardiac resynchronization therapy with defibrillation

Eplerenone reduces new onset atrial fibrillation and flutter in patients with class 2 heart failure

Researchers identify new drug resistant protein in breast cancer

Australians discover treatment for very common female infection

Salk researchers successfully edit diseased gene in patient-specific induced pluripotent stem cells

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

Stimulating electrode array assists paralyzed man to regain voluntary movements of limbs

FDA approves SUTENT for treatment of pancreatic NET

Roundup: Kan. exchange blueprint coming soon; 'Most favored nation' ban passes in Conn.; Anti-fraud repeal in Calif.

DFG to fund 60 million euros for 18 new Research Training Groups

Medicine, osteopathy, physical therapy and chiropractic colleges collaborate to study safety in spinal manipulation

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News